Plasmapheresis
7
1
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Effects of Plasmapheresis on Aging Biomarkers
Plasmapheresis: a Multi-modal Approach
Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis